277 related articles for article (PubMed ID: 26724512)
1. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications.
Singh MN; Lacro RV
Can J Cardiol; 2016 Jan; 32(1):66-77. PubMed ID: 26724512
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
Lacro RV; Dietz HC; Wruck LM; Bradley TJ; Colan SD; Devereux RB; Klein GL; Li JS; Minich LL; Paridon SM; Pearson GD; Printz BF; Pyeritz RE; Radojewski E; Roman MJ; Saul JP; Stylianou MP; Mahony L;
Am Heart J; 2007 Oct; 154(4):624-31. PubMed ID: 17892982
[TBL] [Abstract][Full Text] [Related]
3. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.
Chiu HH; Wu MH; Wang JK; Lu CW; Chiu SN; Chen CA; Lin MT; Hu FC
Mayo Clin Proc; 2013 Mar; 88(3):271-6. PubMed ID: 23321647
[TBL] [Abstract][Full Text] [Related]
4. The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers.
Möberg K; De Nobele S; Devos D; Goetghebeur E; Segers P; Trachet B; Vervaet C; Renard M; Coucke P; Loeys B; De Paepe A; De Backer J
Int J Cardiol; 2012 Jun; 157(3):354-8. PubMed ID: 21239069
[TBL] [Abstract][Full Text] [Related]
5. Update on Clinical Trials of Losartan With and Without β-Blockers to Block Aneurysm Growth in Patients With Marfan Syndrome: A Review.
Hofmann Bowman MA; Eagle KA; Milewicz DM
JAMA Cardiol; 2019 Jul; 4(7):702-707. PubMed ID: 31066871
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome.
Mueller GC; Stierle L; Stark V; Steiner K; von Kodolitsch Y; Weil J; Mir TS
Heart; 2014 Feb; 100(3):214-8. PubMed ID: 24270746
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.
Brooke BS; Habashi JP; Judge DP; Patel N; Loeys B; Dietz HC
N Engl J Med; 2008 Jun; 358(26):2787-95. PubMed ID: 18579813
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
Thakur V; Rankin KN; Hartling L; Mackie AS
Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.
Lacro RV; Guey LT; Dietz HC; Pearson GD; Yetman AT; Gelb BD; Loeys BL; Benson DW; Bradley TJ; De Backer J; Forbus GA; Klein GL; Lai WW; Levine JC; Lewin MB; Markham LW; Paridon SM; Pierpont ME; Radojewski E; Selamet Tierney ES; Sharkey AM; Wechsler SB; Mahony L;
Am Heart J; 2013 May; 165(5):828-835.e3. PubMed ID: 23622922
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome.
Al-Abcha A; Saleh Y; Mujer M; Boumegouas M; Herzallah K; Charles L; Elkhatib L; Abdelkarim O; Kehdi M; Abela GS
Am J Cardiol; 2020 Aug; 128():101-106. PubMed ID: 32650901
[TBL] [Abstract][Full Text] [Related]
12. Atenolol versus losartan in children and young adults with Marfan's syndrome.
Lacro RV; Dietz HC; Sleeper LA; Yetman AT; Bradley TJ; Colan SD; Pearson GD; Selamet Tierney ES; Levine JC; Atz AM; Benson DW; Braverman AC; Chen S; De Backer J; Gelb BD; Grossfeld PD; Klein GL; Lai WW; Liou A; Loeys BL; Markham LW; Olson AK; Paridon SM; Pemberton VL; Pierpont ME; Pyeritz RE; Radojewski E; Roman MJ; Sharkey AM; Stylianou MP; Wechsler SB; Young LT; Mahony L;
N Engl J Med; 2014 Nov; 371(22):2061-71. PubMed ID: 25405392
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.
Pitcher A; Spata E; Emberson J; Davies K; Halls H; Holland L; Wilson K; Reith C; Child AH; Clayton T; Dodd M; Flather M; Jin XY; Sandor G; Groenink M; Mulder B; De Backer J; Evangelista A; Forteza A; Teixido-Turà G; Boileau C; Jondeau G; Milleron O; Lacro RV; Sleeper LA; Chiu HH; Wu MH; Neubauer S; Watkins H; Dietz H; Baigent C;
Lancet; 2022 Sep; 400(10355):822-831. PubMed ID: 36049495
[TBL] [Abstract][Full Text] [Related]
14. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.
Radonic T; de Witte P; Baars MJ; Zwinderman AH; Mulder BJ; Groenink M;
Trials; 2010 Jan; 11():3. PubMed ID: 20067609
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.
Detaint D; Aegerter P; Tubach F; Hoffman I; Plauchu H; Dulac Y; Faivre LO; Delrue MA; Collignon P; Odent S; Tchitchinadze M; Bouffard C; Arnoult F; Gautier M; Boileau C; Jondeau G
Arch Cardiovasc Dis; 2010 May; 103(5):317-25. PubMed ID: 20619242
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes.
Sandor GG; Alghamdi MH; Raffin LA; Potts MT; Williams LD; Potts JE; Kiess M; van Breemen C
Int J Cardiol; 2015 Jan; 179():470-5. PubMed ID: 25465809
[TBL] [Abstract][Full Text] [Related]
17. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Teixido-Tura G; Forteza A; Rodríguez-Palomares J; González Mirelis J; Gutiérrez L; Sánchez V; Ibáñez B; García-Dorado D; Evangelista A
J Am Coll Cardiol; 2018 Oct; 72(14):1613-1618. PubMed ID: 30261963
[TBL] [Abstract][Full Text] [Related]
18. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome.
Bhatt AB; Buck JS; Zuflacht JP; Milian J; Kadivar S; Gauvreau K; Singh MN; Creager MA
Vasc Med; 2015 Aug; 20(4):317-25. PubMed ID: 25795452
[TBL] [Abstract][Full Text] [Related]
19. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome.
Selamet Tierney ES; Feingold B; Printz BF; Park SC; Graham D; Kleinman CS; Mahnke CB; Timchak DM; Neches WH; Gersony WM
J Pediatr; 2007 Jan; 150(1):77-82. PubMed ID: 17188619
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome.
Yetman AT; Bornemeier RA; McCrindle BW
Am J Cardiol; 2005 May; 95(9):1125-7. PubMed ID: 15842990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
